© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Krystal Biotech, Inc. (KRYS) stock declined over -0.54%, trading at $268.54 on NASDAQ, down from the previous close of $270.00. The stock opened at $270.01, fluctuating between $262.40 and $271.05 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 267.86 | 275.75 | 267.86 | 270.00 | 389.16K |
| Apr 13, 2026 | 259.12 | 268.10 | 256.56 | 267.41 | 240.86K |
| Apr 10, 2026 | 258.87 | 259.89 | 255.61 | 259.00 | 162.52K |
| Apr 09, 2026 | 262.46 | 262.86 | 252.30 | 258.33 | 228.21K |
| Apr 08, 2026 | 267.42 | 272.12 | 262.27 | 264.22 | 298.37K |
| Apr 07, 2026 | 261.21 | 264.80 | 257.08 | 263.99 | 244.98K |
| Apr 06, 2026 | 260.95 | 266.63 | 260.53 | 261.80 | 238.42K |
| Apr 02, 2026 | 252.62 | 260.99 | 252.62 | 260.95 | 203.76K |
| Apr 01, 2026 | 260.97 | 264.00 | 255.48 | 258.91 | 347.36K |
| Mar 31, 2026 | 252.00 | 260.47 | 242.00 | 258.32 | 293.96K |
| Mar 30, 2026 | 247.58 | 249.46 | 242.48 | 246.94 | 418.51K |
| Mar 27, 2026 | 248.11 | 249.60 | 242.26 | 245.39 | 288.15K |
| Mar 25, 2026 | 251.04 | 257.65 | 250.91 | 254.95 | 240.46K |
| Mar 24, 2026 | 248.70 | 252.83 | 243.18 | 247.09 | 252.41K |
| Mar 23, 2026 | 254.25 | 255.99 | 247.37 | 250.08 | 274.67K |
| Mar 20, 2026 | 258.91 | 263.75 | 249.38 | 251.68 | 835.39K |
| Mar 19, 2026 | 250.83 | 258.34 | 249.10 | 258.00 | 226.44K |
| Mar 18, 2026 | 256.08 | 257.58 | 250.50 | 250.83 | 225.29K |
| Mar 17, 2026 | 251.89 | 259.27 | 249.74 | 256.33 | 227.26K |
| Mar 16, 2026 | 251.78 | 255.05 | 246.00 | 250.16 | 185.55K |
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Employees | 275 |
| Beta | 0.51 |
| Sales or Revenue | $50.70M |
| 5Y Sales Change% | 19.367% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |